Noreen Inc is developing a protein engineering platform that uses controlled enzymatic hydrolysis, peptide characterization, fractionation, and sensory optimization to create differentiated egg-derived protein and peptide ingredients. The initial focus is improved dissolution, low foam, and superior sensory quality in high-protein beverages, with future applications for frozen desserts, nutrition bars, mousse, marshmallow, and sports/clinical nutrition.
Egg white is a complete, high-quality protein, but at high concentrations it can create formulation challenges such as poor solubility, low dispersibility, excessive foaming, high viscosity, thermal instability, and off-flavors such as bitterness. Noreen Inc is developing a platform that combines controlled enzymatic hydrolysis with peptide characterization, fractionation, and sensory optimization to produce egg-derived protein and peptide ingredients with improved functional and sensory characteristics. This application-driven approach is designed to generate differentiated ingredients suitable for B2B supply, co-development, and licensing. The initial application is a high-protein beverage, with planned expansion to frozen desserts, bars, mousse, marshmallow, and sports/clinical nutrition.
The proposed platform follows a staged research and development program that links processing conditions to measurable outcomes:
The program is designed to deliver a reproducible lab-scale process, ingredient specifications, application data, and a technical package that can support scale-up and commercialization. The platform will focus on food-compatible processing and addresses the trade-off between protein functionality and undesirable flavor or bitterness through targeted fractionation and sensory optimization.
This platform is at the research and development stage. The planned next phases include feedstock characterization, hydrolysis optimization, fraction evaluation, and beverage application screening. Validation will then focus on reproducibility, yield, efficiency, and downstream separation to define critical quality attributes and a preliminary scale-up pathway. A commercially validated, scaled process has not yet been demonstrated; the current program is intended to advance the technology through lab-scale proof and application testing.